Company profile
Tumour Hypoxia Therapy | Coleraine | Stimoxygen
StimOxyGen is a cutting edge technology developed at Ulster University Coleraine that addresses tumour hypoxia with stimulus-responsive, oxygen generating nanoparticles that ultimately improve cancer therapy.
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Jan 2025 to 31 Mar 2026
Cancer is the second leading cause of death worldwide, with more than 19 million new cases accounting for more than 10 million deaths annually. In many cases, a combination of treatments including surgery (if eligible), chemotherapy, radiotherapy, and immunotherapy are used to treat cancer. However, it is well known that a hypoxic (lack of oxygen) and imm...
1 Apr 2024 to 31 Mar 2025
Cancer is the second leading cause of death worldwide, with more than 19 million new cases accounting for more than 10 million deaths annually. In many cases, a combination of treatments including surgery (if eligible), chemotherapy, radiotherapy, and immunotherapy are used to treat cancer. However, it is well known that a hypoxic (lack of oxygen) and imm...
1 Dec 2021 to 28 Feb 2023
Cancer incidence and mortality continues to rise; with 30% of people diagnosed with cancer in 2000, this statistic has increased to 40% in 2020\. Despite increasing cancer prevalence, the major approaches to cancer treatment have largely remained the same i.e., surgery (if eligible), chemotherapy, and radiotherapy and depending on the jurisdiction up to 5...
